Ebselen - Sound Pharmaceuticals

Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Nattermann; Sound Pharmaceuticals; University of Oxford
  • Class Antiulcers; Azoles; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar disorders; Hearing loss; Meniere's disease; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 10 Oct 2017 University of Oxford, Stanley Medical Research Institute and Sound Pharmaceuticals plans a phase II trial for Bipolar disorders in United Kingdom (PO) in October 2017 (NCT03013400) (EudraCT2015-000323-86)
  • 03 Oct 2017 Phase-II clinical trials in Meniere's disease in USA (PO)
  • 03 Oct 2017 Efficacy and adverse events data from a phase Ib/II trial in Meniere's disease released by Sound Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top